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Abstract
Background Biosimilars are expected to emerge as a rapidly growing segment of the biopharmaceutical industry. However, 
the biosimilar industry faces multiple challenges and obstacles in developing and marketing these complex products. Diver-
gent regulatory framework in emerging countries adds to repetitive trials and increased cost of biosimilar development, 
delaying the approval process. Due to such roadblocks, healthcare systems and patients are yet to realize the full benefits 
of biosimilars.
Objectives The aim of this exploratory study was to specifically identify the challenges faced by the industry in emerging 
countries including Brazil, Russia, India, China, South Africa, Turkey and Mexico (BRICS-TM), pertaining to biosimilar 
development and the regulatory approval process. In particular, this study aims to understand the perceptions of industry on 
the barriers faced by them in terms of complexity, costs for biosimilar development and time-to-market for biosimilar product.
Methods A semi-quantitative questionnaire was designed based on secondary research. A total of 93 industry personnel and 
representatives from 14 trade associations from the BRICS-TM countries with 15-year minimum experience were identi-
fied and invited to take part in the study and participate in interviews, which were recorded verbatim. Data processing and 
analysis was carried out; descriptive statistics were used for quantitative data and content analysis was employed to generate 
themes for qualitative data.
Results Of the 107 biopharmaceutical industry and trade association representatives invited to participate in the study, 
respondents from 33 biopharmaceutical companies agreed to take part and underwent the interviews. The industry person-
nel perceived biosimilar guidelines and approval processes as being protracted and in a state of evolution. The absence of 
an abridged approval pathway limited effectiveness of the regulatory process. The biggest hurdles in the development of 
biosimilar dossiers were the sourcing of the reference biological product and expectations around confirmatory clinical trials 
by the agencies. The non-comprehensive implementation of a stepwise approach resulting in unnecessary toxicity studies was 
also reported as a major challenge. The authors recommend further primary research with BRICS-TM regulatory agencies 
in order to propose a simplified pathway for development and approval.
Conclusions Lack of standardized biosimilar development criteria and regulatory convergence across BRICS-TM agencies 
has led to challenges in multi-country development programmes for these medicines, in turn impacting the ability of industry 
to launch newer and more affordable biosimilars.
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1 Introduction
Despite the high cost of therapy, the clinical efficacy and 
safety profile of biologic medicines has propelled huge 
growth of these treatments across the world [1]. Today, 
biologics are one of the largest and fastest growing sectors 
of the prescription product market with the market share 
of biologics growing steadily relative to small molecules. 
The new product pipelines of leading companies suggest 
that this growth dynamic will continue and be broad-based 
across various therapeutic areas [2].
However, the high cost of therapy with original bio-
logics puts them out of reach for many across the world. 
Biosimilar medicines are usually made available at a sig-
nificant discount to original biologics, and therefore have 
the potential to improve access and create valuable savings 
for patients and healthcare systems [3]. Biosimilars are 
products that are similar to a reference biologic product 
(RBP) and according to the United States Food and Drug 
Administration (US FDA), need to be highly similar to the 
approved reference product without any clinically mean-
ingful differences in terms of safety, purity and potency 
[4].
When the concept of biosimilars first emerged, it gen-
erated high expectations from the access and cost sav-
ings potential that the medicines could bring to patients 
globally. However, due to several roadblocks, healthcare 
systems are yet to realize the full benefits of biosimilars 
[5]. Significant challenges persist from the perspective of 
all key stakeholders involved, that is, regulators, industry, 
physicians and patients.
The biosimilar industry faces multiple challenges to 
develop and market these complex products [6]. Com-
pared with the well-established approval process for new 
chemical entities (NCEs) and small-molecule generics, the 
framework for approval of new biological entities (NBEs) 
and biosimilar products is evolving in stages across most 
of the developing countries. Biosimilar developers face 
obstacles to receiving appropriate advice, which leads to 
delays in product launches and late returns on investments 
[6]. In addition, most of the emerging market agencies 
have unclear regulatory processes with little global conver-
gence. This makes global or multi-country developments 
expensive, lengthy and risky.
The cost to develop and gain approval for a biosimilar 
medicine in the US ranges between US$100 million to 
US$200 million [7]. This is significantly different from the 
cost of developing a small molecule generic, which typi-
cally ranges from US$1 million to US$5 million [7]. Bio-
similar development costs are high due to greater clinical 
trial requirements and a need for sophisticated manufactur-
ing facilities and cutting-edge technologies. Additionally, 
there is a requirement for investment in more technically 
skilled and competent manpower resources alongside 
direct promotional activities aimed at physicians and 
patients. Due to the inherent variability of biologics, the 
reproducibility of biosimilars is a big challenge and thus 
they are more complex to develop and manufacture [7]. 
The timelines for development and approval of biosimilars 
is also much longer than that of the small molecule gener-
ics. A United States Federal Trade Commission Report 
states that it takes 8–10 years to develop a biosimilar com-
pared with 3–5 years for a small molecule generic [7].
Overall, challenges faced by the industry in complexity, 
costs, time-to-market and regulatory pathway for develop-
ment and approval have resulted in a significant entry bar-
rier for new players in this space. This, in turn, has led to 
suboptimal patient access to biosimilars [8].
The aim of this exploratory study was to specifically iden-
tify the challenges faced by the industry in Brazil, Russia, 
India, China, South Africa, Turkey and Mexico (BRICS-
TM) pertaining to biosimilar development and the approval 
processes, including concerns on pricing and market access.
This study is a part of a larger research programme cov-
ering regulatory agencies, industry, physicians and patients 
in order to validate findings of some secondary research, 
published in the review article “Quality, non-clinical and 
clinical considerations for biosimilar monoclonal antibody 
development: EU, WHO, USA, Canada and BRICS-TM 
regulatory guidelines” [9].
2  Methods
A semi-quantitative questionnaire was compiled (in Eng-
lish), targeting various topics of concern for the biopharma-
ceutical industry based on information from the literature, 
entitled Biosimilar Development, Submission and Review 
(BDSR). The BDSR questionnaire consists of four parts: 
general information on biosimilar experience of the com-
pany; regulatory biosimilar approval process challenges and 
suggestions on areas of improvement; challenges pertain-
ing to biosimilar development and suggestions on areas of 
improvement; and concerns faced by the industry in the area 
of biosimilar pricing and access (see supplementary infor-
mation in the electronic supplementary material [ESM]). 
The industry questionnaire underwent several refinement 
processes, including content validation by two industry 
experts, in order to produce the final version.
Two target groups across the BRICS-TM countries were 
selected: active industry personnel with experience of over 
15 years in the biosimilar space; and representatives from 
the pharmaceutical trade associations who have member 
companies with marketed biosimilar products.
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Recent estimates of companies marketing and developing 
biosimilar medicines range between 100 and 182 [10, 11]. 
Most of these companies are based in high-income, devel-
oped countries [12], with fewer active industry players in 
developing countries. Also, the expertise and knowledge 
level of most of the industry personnel in developing coun-
tries are lower. Those who declined to take part in the study 
offered reasons of confidentiality issues and time constraint. 
Industry personnel could be contacted relatively easily in 
India as the researcher was from the same country and had 
prior contacts and hence could reach the industry person-
nel. However, a similar network of industry personnel in the 
other countries was difficult to establish and therefore this 
could have impacted recruitment of participants from these 
countries. Efforts were made to improve the response rate 
by carrying out three follow-ups with the non-responders.
A secondary online search was performed using search 
terms such as biosimilar developer; biosimilar marketer; 
biopharmaceutical company; biosimilar approvals; trade 
associations; monoclonal antibodies and specific biological 
molecules. Sources included review articles, correspond-
ence, meeting reports, opinions and abstracts obtained 
from Google scholar, websites of BRICS-TM health agen-
cies, the University of Hertfordshire library and regulatory 
focus journals. The online secondary search was conducted 
from January 2020 to March 2020, resulting in a list of 41 
biopharmaceutical companies marketing or developing bio-
similars in BRICS-TM countries as well as 14 active trade 
associations within these countries, which included manu-
facturers and marketers of biosimilars.
The trade associations identified were Pharmaceuti-
cal Research Industry Association, Brazil; Pró Genéricos 
- Associação Brasileira das Indústrias de Medicamentos 
Genéricos, Brazil; Association of International Pharma-
ceutical Manufacturers, Russia; Association of Biotechnol-
ogy Led Enterprises (ABLE), India; Indian Pharmaceuti-
cal Association (IPA); China Pharmaceutical Industry 
Association; Chinese Pharmaceutical Association; South 
Africa Association of Pharmacists in Industry; The Inno-
vative Pharmaceutical Association South Africa (IPASA); 
International Generic and Biosimilar Medicines Association 
(IGBA) South Africa; Turkey International Trade Associa-
tion; Pharmaceuticals Manufacturers Association of Turkey 
(IEIS); Mexican Association of Pharmaceutical Research 
Industries; and International Generic and Biosimilar Medi-
cines Association (IGBA), Mexico.
A total of 93 industry personnel working within the 
identified companies and representatives from all 14 trade 
associations were invited to take part in the study. Contact 
details of industry personnel and trade associations were 
obtained through company websites, trade association web-
sites, LinkedIn pages and through industry contacts of the 
authors. The study was based on an electronic questionnaire 
and, following completion, the participants were interviewed 
face-to-face (average of 45 minutes’ duration) using an 
online platform in order to verify their responses, expand 
on their views and minimise bias due to misinterpretation. 
Confidentiality issues were cited by 14 industry personnel 
as a reason for non-participation and 46 did not respond at 
all. None of the 14 trade associations responded. In order to 
minimize bias arising from differences between responders 
and non-responders, three follow ups were carried out to try 
and maximize the response rate. However, this did not lead 
to an improved response rate (Fig. 1). Affirmative responses 
were received from 33 industry personnel who completed a 
web-based questionnaire.
Subsequently, interviews were conducted with the 33 
study participants via phone call or web meetings to verify 
their responses, fill the gaps and provide additional com-
ments based on their level of experience. This was carried 
out between March and October 2020.
2.1  Data Processing and Analysis
This was an exploratory study attempting to generate a 
hypothesis; therefore, no sample size calculation was car-
ried out. However, the sample size may not be adequate in 
generalizing the results and bias could have been introduced 
as a result of purposive sampling. Since no statistical test 
was applied to the data, this removed the possibility of bias 
due to such tests. Data processing and analysis was carried 
out using Microsoft Excel and the Statistical Product and 
Service Solutions (SPSS) analytical software; descriptive 
statistics (i.e. mean, standard deviation, median, range and 
mode) were used for quantitative data, and content analysis 
was employed to generate themes and sub-themes for quali-
tative data.
2.2  Ethics Approval
The study was approved by the Health, Science, Engineering 
and Technology ECDA, University of Hertfordshire. Proto-
col number for the same is aLMS/PGR/UH/03332(1).
3  Results
3.1  Demographic Characteristics of the Study 
Participants
Out of the 107 personnel from the biopharmaceutical indus-
try and representatives from trade associations contacted for 
the study, 33 agreed to take part. Of those that completed 
the study, 6 were from Brazil, 4 from Russia, 15 from India, 
1 from China, 1 from South Africa, 1 from Turkey and 5 
from Mexico. The respondents were senior level executives 
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with a designation of Vice President and above, represent-
ing Research and Development, Regulatory, Manufacturing 
and Marketing divisions of biopharmaceutical companies. 
The demographic characteristics of the study participants 
are presented in Table 1.
3.2  Biopharmaceutical Industry of BRICS‑TM
The study participants had varied experience in the area of 
biosimilars. More than 58% of the participants belonged to 
BRICS-TM companies that have been involved in biosimilar 
development for more than a decade (11 years and above), 
while 35% of these were engaged in biosimilar development 
for 6–10 years. There were only 6% of respondents whose 
companies had experience of < 5 years.
Thirty (90%) of the participating companies were mar-
keting biosimilars. Of these, only 11 (37%) were marketing 
less than three biosimilar molecules, while most have com-
mercialized between three and ten molecules. Four (13%) 
companies are marketing more than ten biosimilars in these 
emerging markets; 59% of these companies are developing 
products for commercializing in other emerging markets 
and 78% have an in-house biologics manufacturing facility. 
Therefore, the nature and characteristics of the companies 
that took part in this study confirmed their suitability for 
continuing the interview for the other parts of the question-
naire involving the challenges of biosimilar development and 
regulatory processes.
3.3  Biosimilar Guidelines and Approval Process
3.3.1  Guidelines, Evaluation and Approval Process
In response to a question on the guidelines and approval 
process for biosimilars, only 26% considered the guidelines 
to be well defined and transparent with an efficient review 
process. The guidelines were considered to be evolving 
with a tedious review process by 64% of respondents and 
the remaining 10% felt that there was a lack of clarity and 
transparency with guidelines subject to different interpreta-
tion, see Fig. 2.
Collated list of 41 companies marketing/ developing 
biosimilar medicines in BRICS-TM countries
Collated list of 14 active biopharmaceutical trade 
associations in BRICS-TM, with member companies 
marketing biosimilar medicines 
93 industry personnel and representatives from 14 trade associations 
were requested for interviews via emails and phone calls (n = 107)




Drop-outs (n = 0)
Completion & analysis (n = 33)
Fig. 1  CONSORT diagram. BRICS-TM Brazil, Russia, India, China, South Africa, Turkey, Mexico
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In India, 13 out of 15 respondents indicated an evolv-
ing and tedious regulatory process. Participants noted that 
the coordination between two government bodies separately 
reviewing non-clinical (Department of Biotechnology—
DBT) and clinical data (Central Drugs Standard Control 
Organisation—CDSCO) has much scope for improvement. 
In Mexico too, three out of five respondents indicated the 
evolving guidelines and tedious regulatory process for 
biosimilars. Notably in Brazil, four out of six respondents 
indicated that there were well defined, transparent guidelines 
and an efficient review process. This could, in part, be attrib-
uted to the fact that all meetings between industry and the 
Agência Nacional de Vigilância Sanitária (ANVISA—the 
Brazil National Health Surveillance Agency) are recorded 
and can be retrieved and referred to. With regards to the 
transparency of the regulatory review process for biosimi-
lars, 43% of BRICS-TM respondents stated that the review 
process was generally transparent on the main milestones 
but the decision-making process for each milestone was non-
transparent. However, 24% of BRICS-TM reported that the 
review process was non-transparent.
The participants were asked to rate (on a 5-point scale 
where 1 = low concern and 5 = significant challenge) the 
key challenges in the review and evaluation of biosimilar 
dossiers by the respective country’s regulatory agency. It 
is notable that all the identified challenges were rated 3 
(moderate challenge) and above, indicating that these were 
all significant issues across the countries (Fig. 3). ‘Process 
inefficiency’ emerged as the single highest concern with a 
median rating of 4 and a mode value of 5. ‘Inadequate com-
munication channel between the industry and the agency’ 
and ‘Lack of consultation with applicant company’ emerged 
as the second biggest concerns with a median rating of 3.5 
and a mode value of 4 for both parameters.
Some of these challenges could be mitigated by the timely 
provision of appropriate scientific advice from the agency 
to the company. However, in response to a question on this 
matter, it appeared that about 60% of respondents across 
BRICS-TM either did not receive advice or received advice 
that was inadequate. This concern is more pressing in Russia 
where there is no possibility of interaction with the Ministry 
of Health (MoH) on this subject. Notably, all respondents 
from Brazil confirmed provision of adequacy of scientific 
advice from ANVISA.
3.3.2  Efficiency and Effectiveness of Approval Process
The approval timelines of biosimilar applications did not 
emerge as a significant challenge with the BRICS-TM agen-
cies. Most regulatory agencies have an average timeline of 
24 months, with CDSCO India and MoH Russia having a 
shorter timeline of 6–12 months. In Mexico, the average 
approval timelines by Comisión Federal para la Protec-
ción contra Riesgos Sanitarios (COFEPRIS) was reported 
as 9–12 months by the respondents. In India specifically, 
the most frequent timeline was reported as being 6 months. 
The expected optimal approval timelines by companies 
were reported to be in the range of 9–12 months across 
the BRICS-TM countries, with 9 months being the most 
frequently reported. The largest gap between the agency 
practice and the industry expectation occurred in Brazil (12 
Table 1  Demographic characteristics of the study participants
BD Business Development, R&D Research and Development, NA Not 
Applicable
a Technical operations includes respondents who are Chief Scientific 
Officers or working in Manufacturing, Operations, and Quality Con-
trol departments
Function BD Technical 
 operationsa
Regulatory R&D
Brazil (total number of respondents: 6)
 Age group (years) 40–49 NA 33–40 NA
 Number of respondents 3 NA 3 NA
 Males 3 NA 2 NA
 Females 0 NA 1 NA
Russia (total number of respondents: 4)
 Age group (years) NA 36–60 45 NA
 Number of respondents NA 2 2 NA
 Males NA 2 2 NA
 Females NA 0 0 NA
India (total number of respondents: 15)
 Age group (years) 45–48 48 39–55 61
 Number of respondents 5 1 8 1
 Males 5 1 8 1
 Females 0 0 0 0
China (total number of respondents: 1)
 Age group (years) 49 NA NA NA
 Number of respondents 1 NA NA NA
 Males 1 NA NA NA
 Females 0 NA NA NA
South Africa (total number of respondents: 1)
 Age group (years) NA NA 40 NA
 Number of respondents NA NA 1 NA
 Males NA NA 1 NA
 Females NA NA 0 NA
Turkey (total number of respondents: 1)
 Age group (years) NA NA 45 NA
 Number of respondents NA NA 1 NA
 Males NA NA 1 NA
 Females NA NA 0 NA
Mexico (total number of respondents: 5)
 Age group (years) NA 47 & 58 58 36 & 52
 Number of respondents NA 2 1 2
 Males NA 2 1 2
 Females NA 0 0 0
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months). The study participants representing the BRICS-
TM countries highlighted an absence of an abridged review 
pathway, although in Mexico, 80% of respondents indi-
cated an abridged review pathway being followed by their 
agency. In response to a question on fast-track approvals of 
biosimilars, 55% of respondents reported that such proce-
dures exist. However very few have had success in avail-
ing of such approvals, except in the case of orphan drugs 
and recently in the case of medicines for the treatment of 
COVID-19 (e.g., itolizumab was approved by CDSCO India 
for restricted emergency use in Acute Respiratory Distress 
Syndrome [ARDS] caused by COVID-19, in July 2020. 
This monoclonal antibody was approved in India in 2013, 
and the additional indication was approved via a fast-track 
procedure).
Most countries require pricing approval for biosimilars 
before commercialization. This process is not unduly long 
with timelines ranging from 2 to 6 months.
3.4  Development Parameters
3.4.1  Reference Biologic Product (RBP) Selection
The BRICS-TM agencies provide clarity in terms of the RBP 
to be used for each biosimilar development and the list of 
countries from which sourcing of a foreign acceptable com-
parator (FAC) is admissible.
Fig. 2  Industry feedback on guidelines and approval process
Fig. 3  Challenges in review and evaluation of biosimilar dossier
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While the industry may have clarity around the reference 
product and the country from which it is expected to be 
sourced, sourcing of the RBP remains a key challenge.
3.4.1.1 Multiple Lots of RBP In order to meet the require-
ment for statistical justification of analytical similarity of the 
biosimilar with the original biologic, multiple lots of the ref-
erence product need to be sourced, as reported by 29 (88%) 
of the participants. The exact number of batches are often 
not specified and may vary from case to case, and it is open 
to industry interpretation. Individual responses from within 
countries vary widely but the frequency analysis revealed a 
mode of 3–10 batches of different ages except South Africa, 
where it was indicated there was no expectation for multiple 
batches. The sourcing of multiple batches of the RBP is a 
significant challenge for industry, as indicated by 70% of the 
companies. Content analysis of the participants’ comments 
showed that concurrent availability of multiple lots of the 
RBP in the market at any given point of time is a key hurdle.
3.4.1.2 Quantity of  RBP Even if available, the quantity 
of product required per batch for various tests and studies 
(characterizations, comparability studies, clinical studies) 
can be difficult to source. Large quantities of RBP required 
to perform comparative clinical safety and efficacy studies 
increases the overall cost of development.
3.4.1.3 RBP from  a  Single Drug Substance The innovator 
usually manufactures the drug substance on a large scale. 
Therefore, multiple product batches can come from a single 
drug substance, which complicates the efforts of biosimilar 
developers to get drug product batches from different drug 
substances. Sourcing multiple batches of the same biologi-
cal substance leads to limited variation in analytical results, 
which in turn complicates the justification for product speci-
fications with the regulator. In order to remedy such a situ-
ation, the biosimilar manufacturer often has to set up strin-
gent analytical specifications, which subsequently results in 
manufacturing difficulties, such as non-compliance to strin-
gent standards.
3.4.1.4 Change in  Manufacturing Process of  RBP If the 
innovator decides to change the manufacturing process and 
obtains approval for the same, a fresh development process 
with new batches needs to be initiated by the biosimilar 
manufacturer.
3.4.1.5 RBP Non‑Availability in Open Market In Russia, a 
specific issue is that all biologics are procured directly by 
the government from the distributors, resulting in no avail-
ability of the product in the open market for procurement. 
Consequently, all these factors result in sizable time and 
cost escalation for the companies developing biosimilars.
3.4.2  Criteria for Biosimilarity
Criteria for biosimilarity encompasses comparative phys-
ico-chemical and biological characterization, in vitro non-
clinical studies, in vivo safety data and confirmatory clini-
cal safety and efficacy studies.
In response to a question on challenges to prove bio-
similarity, the study participants from BRICS-TM rated 
‘confirmatory clinical safety and efficacy study’ as their 
highest concern with a mean rating of 2.4 on a scale of 1 
to 3. The most frequent rating value was 3 with 22 of 33 
respondents rating this as a ‘significant challenge’. The 
mean rating of other parameters included ‘comparative 
physico-chemical and biological characterization (qual-
ity)’; and ‘in vitro or in vivo non-clinical study’, which 
were rated as 2 (i.e., moderate challenge), but not as 
high as ‘confirmatory clinical safety and efficacy study’ 
(Fig. 4).
In terms of efficacy and safety studies, the study partici-
pants reported that the cost of trials, large sample size for 
trials, lead time for patient recruitment and significant drop 
out rates were some of the major operational issues in con-
ducting clinical studies for biosimilars. Companies also face 
lack of expertise to develop in-house bioassay methods for 
biosimilars.
3.4.3  Naming of Biosimilars
The BRICS-TM regulatory agencies mandate the same inter-
national non-proprietary name (INN) for biosimilars as the 
RBP, as reported by 30 (90%) of the companies participating 
in the study. This is different from the approach followed 
by the US FDA, which expects the nomenclature to be in 
accordance with ‘Guiding Principles for Coining United 
States Adopted Names for Drugs’ [13] for each biologic and 
biosimilar [14] (Table 2).
3.4.4  Non‑Clinical Studies
As reported earlier in this article, non-clinical studies for 
biosimilars were not rated as a significant challenge by the 
study participants from the BRICS-TM countries. Further 
details from the responses indicated that though non-clinical 
studies data are mandatory as part of the application, no reg-
ulatory agency mandates that studies be performed locally. 
Content analysis of the free-text comments proposed that 
the regulatory agencies should move towards a step-wise 
approach to development and mandate non-clinical data only 
if absolutely required.
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3.4.5  Clinical Studies
As part of the biosimilar application, most agencies expect 
data from a phase I study (comparative clinical pharmacoki-
netic [PK], pharmacodynamic [PD] or combined PK/PD), 
phase III study (comparative clinical safety and efficacy) 
and phase IV post-marketing surveillance study (includ-
ing follow-up study for immunogenicity). A comparative 
confirmatory clinical study (phase III) is one of the most 
important requirements to be fulfilled as part of the market-
ing authorization of the application. In Sect. 3.3.2 of the 
Results describing criteria for demonstrating biosimilarity, 
it was reported that the companies taking part in this study 
rated ‘confirmatory clinical safety and efficacy study’ as the 
highest concern for them in the development of a biosimilar 
product.
3.4.5.1 Mandatory Local Studies This study needs to be 
performed locally in India, Mexico, Russia and China and 
should be comparative in nature; the reference drug needs to 
be used throughout the study to prove comparative efficacy 
of the respective biosimilar. Mostly biosimilar applicant 
companies combine the confirmatory clinical and immuno-
genicity studies.
3.4.5.2 Lack of  Clarity on  Study Design There exists lack 
of clarity on certain aspects of these studies, such as study 
types, population, end points, design, paediatric population, 
safety pharmacology expectations and follow-up period.
3.4.5.3 Other Factors The industry also faces challenges in 
the following areas:




4. Availability of a clinical research organization (CRO).
5. Lack of specific and binding scientific advice on clinical 
studies.
Fig. 4  Challenges in demonstrating biosimilarity
Table 2  International Non-proprietary Name (INN) system adopted for biosimilars
ABN Approved Biological Name, AE Adverse Events, BRICS-TM Brazil, Russia, India, China, South Africa, Turkey, Mexico, EMA Euro-
pean Medicines Agency, EU European Union, RBP Reference Biologic Product, TGA Therapeutic Goods Administration, USAN United States 
Adopted Names, US FDA United States Food and Drug Administration
Regulatory agencies INN system
US FDA The FDA appends a unique, 4-letter suffix as per USAN to the INN for each biologic and biosimilar
EMA The EU requires a proprietary name (brand name or company name plus INN), accepts the same INN as the RBP, and 
for AE reporting, the product name and batch number are to be given; barcode is required
TGA Mandatory use of the brand name and Australian ABN for the active ingredient; considering adopting a barcode system
BRICS-TM agencies Biosimilar INN is the same as the RBP across BRICS-TM countries
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These factors were rated by the company participants 
(Fig. 5) across the BRICS-TM, which showed ‘Lack of spe-
cific and binding scientific advice on clinical study design’ 
to be the single biggest challenge with a mean value of 3.5 
and a mode value of 4 (high challenge). ‘Approval of proto-
col by the agency’ and ‘Patient recruitment’ were rated as 
the next biggest obstacles. This outcome further validates 
earlier reported data on inadequacy of scientific advice.
3.4.5.4 Sample Size for  Clinical Studies The BRICS-TM 
[15–21] agencies require confirmatory clinical studies to be 
performed in two arms with a patient ratio of 1:1 for the 
test and reference product. The response from countries was 
markedly variable; however, it was reported that the mini-
mum expectation from the regulatory agencies was 100–200 
patients per arm, or based on statistical powering of the trial, 
whichever was highest.
3.4.5.5 Multi‑Country Development Considering the time 
and cost involved in developing and marketing biosimilars, 
the companies active in this space are those that overcome 
steep entry barriers and are therefore typically large multi-
national players. Despite this, industry players find it difficult 
to develop a global regulatory strategy for biosimilars cov-
ering the emerging markets, due to several hurdles. While 
69% of companies indicated that they are pursuing multi-
country biosimilar developments including for BRICS-TM 
countries, they face obstacles on several fronts (Fig. 6).
In response to a question on these challenges, the par-
ticipants rated ‘Lack of harmonized guideline for biosimilar 
development across BRICS-TM’ and ‘Absence of common 
clinical trial design and approval process across BRICS-TM’ 
as the highest concerns, with a mean of 3.5 on a scale of 1–4 
and a mode value of 4 for both. Other issues such as ‘Accept-
ance of reference biological product across BRICS-TM’ and 
‘Acceptance of foreign patients’ data’ were also rated as a 
‘significant challenge’, with 4 being the most prevalent rat-
ing, signifying all four criteria as critical barriers.
3.5  Pricing and Market Access Concern
A Quintiles and IMS Health (IQVIA) article on biosimilars 
and biobetters published in September 2020 [22] reported 
that the rest of the world (RoW) countries accounted for 
US$0.1 billion sales for follow-on biologics (FOBs) includ-
ing biocomparables versus US$15 billion global sales, as 
of second quarter 2020. It was concluded that there is an 
overall low coverage of biologics, and FOBs are an emerging 
sector where sales remain low. Further, on their own, RoW 
countries are unable to justify the cost of development for 
biosimilar projects [22].
This study delved into the reasons for limited access for 
patients and entry barriers for the industry. ‘Innovator patent 
term and strategy’ and ‘Higher cost of therapy of biosimi-
lars as compared to small molecule medicines’ were rated 
as the highest barriers to access with a mean rating of 3.6 
and 3.4, respectively. The next biggest obstacles were rated 
to be ‘Challenges pertaining to regulatory framework for 
development and approval of biosimilars’ and ‘Less num-
bers of active industry players in biosimilar segment’. Apart 
from the concerns around patent terms of original biologics, 
Fig. 5  Challenges in clinical study. CRO Clinical Research Organization
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the other three challenges can be substantially mitigated by 
facilitating ease of development and approval of global 
biosimilars and enabling more competition in this space. 
Related to this, companies were asked about specific issues 
that acted as entry barriers into this space. ‘Late and unsure 
return on investment considering high cost involved’ and 
‘Prohibitive cost of clinical trials for biosimilars’ were rated 
as the highest challenges with a median rating of 4.3 and 
4.1, respectively. ‘Lack of in-house expertise and infrastruc-
ture in biosimilars’ and ‘Pressure on pricing from health 
authorities/insurers/procurement authority’ were rated as the 
second-highest barriers with a median rating of 3.5 and 3.4, 
respectively (Fig. 7).
Fig. 6  Development challenges in BRICS-TM market. BRICS-TM Brazil, Russia, India, China, South Africa, Turkey, Mexico
Fig. 7  Entry barriers for industry players to be active in biosimilar space. BRICS-TM Brazil, Russia, India, China, South Africa, Turkey, Mexico
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4  Discussion
The biopharmaceutical industry faces several challenges in 
the development and registration of biosimilars in BRICS-
TM countries. The result of this exploratory research has 
highlighted key issues, which are summarized in Table 3. 
Clearly, the results indicate that across the BRICS-TM 
countries, the different functions were mostly aligned in 
their perception of the specific challenges faced by them 
(Table 4).
Biosimilar regulations vary widely across the regula-
tory agencies in emerging economies, with a patchwork 
of applicable rules [23]. In this research, only 26% of 
respondents found the available guidelines transparent 
and the majority felt that communication between indus-
try and the regulatory agency is inadequate and unreliable. 
Process inefficiencies can often be attributed to the lack of 
expert resources within the biologics departments of the 
regulatory agencies [24]. However, building capacity and 
expertise in a national regulatory authority is a long-term 
process and quick resolutions lie in relying on informa-
tion from other regulatory authorities or joint or abridged 
review models [25]. Also, transparency in the regulatory 
evaluation process would greatly contribute to establish-
ing confidence within the industry and the recording and 
retrieval of meetings as followed by ANVISA is an exam-
ple of ‘good review practice’ that can be emulated.
The RBP sourcing comes across as a major hurdle for 
most companies [25]. A greatly simplified basis for selecting 
a reference comparator, that does not require conducting new 
bridging studies, has been proposed and justified based on 
the relevant scientific data in an opinion paper [26]. In an 
article on ‘The importance of Global Regulatory Harmoni-
zation for Biosimilar Medicines’ by the IGBA [27], use of 
a global comparator product and waiving of bridging stud-
ies is highlighted as a key proposal to enable multi-country 
development. A World Health Organisation (WHO) survey 
result of 20 countries also reiterated these challenges [28]. A 
common approach to the RBP definition, harmonized expec-
tations for the number of batches to be used for analytical 
similarity, acceptance to source RBP across BRICS-TM 
countries and establishment of an independent agency to 
supply RBP with varied drug substance lots in the absence 
of the product in the open market will enable multi-country 
development.
A key improvement area for regulatory agencies in the 
emerging economies could be adoption of a ‘step-wise’ 
approach for biosimilar development [24]. This will reduce 
the unnecessary non-clinical studies in cases where there 
is proven similarity in physicochemical characterization 
between the test and reference product.
Table 3  Summary of critical 
challenges identified, based on 
primary research
BRICS-TM Brazil, Russia, India, China, South Africa, Turkey, Mexico, RBP Reference Biological Product
Aspects Critical challenges identified
Guidelines, evaluation and approval process Evolving guidelines with tedious review process
Process inefficiency
Inadequate communication channel with agency
Process effectiveness Absence of abridged review pathway
Development parameters Reference biologic product
– Sourcing of multiple lots within stipulated 
timeframe
– Sourcing acceptable from limited countries
– Large quantity required for characterization 
and clinical study




– Mandatory  in vitro/in vivo studies, often not 
justified
Confirmatory clinical safety and efficacy studies
– Lack of specific and binding scientific advice
– Lack of harmonized guideline for biosimilar 
development across BRICS-TM
– Absence of common clinical trial design and 
approval process across BRICS-TM
Market access and pricing Late and unsure return on investment consider-
ing high cost involved
Prohibitive cost of clinical trials for biosimilars
Pressure on pricing from health authorities/ 
insurers/ procurement authority
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Further in the development cycle, companies have sin-
gled out the confirmatory clinical safety and efficacy study 
as a major concern. A McKinsey report on biosimilars has 
reiterated that discussion around lowering development costs 
via innovation is essential to ensure a sustainable future [29]. 
Therapeutic equivalence trials account for at least 75% of 
Table 4  Breakdown of challenges in biosimilar development and approval process in BRICS-TM according to functions of the study participants
Identified challenges Country Prevalence of 
responses (%)
Level of con-
cordance of the 
responses
Regulatory affairs (RA)
 Evolving guidelines with tedious review process Brazil 33.3 Low concern
Russia 50 High concern
India 60 High concern
China NA NA
South Africa 100 High concern
Turkey 0 No concern
Mexico 100 High concern
 Confirmatory clinical safety and efficacy studies Brazil 66.67 High concern
Russia 100 High concern
India 80 High concern
China NA NA
South Africa 100 High concern
Turkey 100 High concern
Mexico 0 No concern
 Reliance and absence of abridged review pathway Brazil 33.33 Low concern
Russia 50 High concern
India 100 High concern
China NA NA
South Africa 0 No concern
Turkey 0 No concern
Mexico 0 No concern
Research & development (R&D)
 Mandatory non-clinical studies (in vitro and in vivo studies) Brazil NA NA
Russia NA NA
India 100 High concern
China NA NA
South Africa NA NA
Turkey NA NA
Mexico 100 High concern
 Lack of specific and binding scientific advice Brazil NA NA
Russia NA NA
India 100 High concern
China NA NA
South Africa NA NA
Turkey NA NA
Mexico 100 High concern
 Lack of harmonized guideline for biosimilar development across BRICS-TM Brazil NA NA
Russia NA NA
India 100 High concern
China NA NA
South Africa NA NA
Turkey NA NA
Mexico 100 High concern
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total development costs [29]. Secondary research on biosim-
ilar approvals has revealed that usually no submission gets 
rejected following a full review due to a finding of clinical 
inequivalence between the biosimilar and its RBP if the two 
products have been found to be highly similar in analyti-
cal and PK studies [30]. Hence, powered efficacy studies of 
these biosimilar candidates are of questionable value [30]. 
Moreover, repetition of these studies across countries and 
non-acceptance of foreign patients’ data leads to escalation 
of cost and timelines, jeopardizing the return on investment 
for the developer. A policy paper from IGBA [31] has also 
reiterated the higher relevance of advanced analytical sci-
ence to prove comparability in place of confirmatory clini-
cal data. In addition, WHO is also well positioned on this 
subject in its ‘Guidelines on evaluation of similar biothera-
peutic products (SBPs)’ [32], based on which other regional 
If % outcome of respondents is ≥ 50 = high concern, < 50 = low concern, 0 = no concern
BRICS-TM Brazil, Russia, India, China, South Africa, Turkey, Mexico, NA Not Applicable, RBP Reference Biological Product
Table 4  (continued)
Identified challenges Country Prevalence of 
responses (%)
Level of con-
cordance of the 
responses
Business development (BD)
 Late and unsure return on investment considering high cost involved Brazil 100 High concern
Russia NA NA
India 100 High concern
China 100 High concern
South Africa NA NA
Turkey NA NA
Mexico NA NA
 Pressure on pricing from Health Authorities/Insurers/Procurement Authority Brazil 100 High concern
Russia NA NA
India 80 High concern
China 0 No concern
South Africa NA NA
Turkey NA NA
Mexico NA NA
 Sourcing of multiple RBP lots Brazil 100 High concern
Russia NA NA
India 60 High concern
China 100 High concern




 In-house expertise and infrastructure Brazil NA NA
Russia 50 High concern
India 100 High concern
China NA NA
South Africa NA NA
Turkey NA NA
Mexico NA NA
 Submission and commercialization of three batches of validation Brazil NA NA
Russia 50 High concern
India 75 High concern
China NA NA
South Africa NA NA
Turkey NA NA
Mexico 50 High concern
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guidelines for biosimilars have been modelled into. The 
WHO [32] clearly notes that the demonstration of compa-
rability of an SBP to its RBP in terms of quality (compa-
rability exercise) is a prerequisite for the reduction of the 
non-clinical and clinical data set required for licensure. The 
guidance further elaborates its stand on abbreviated clinical 
development programmes for biosimilar products, citing the 
advancement in the development of analytical methodology 
for characterizing complex biotherapeutic products includ-
ing monoclonal antibodies.
These barriers in the biosimilar space in emerging mar-
kets have led to relatively low patient access to biosimi-
lar medicines when compared to developed markets [6]. 
Patients in these markets stand to gain the greatest increase 
in access as a result of biosimilar competition. There has 
been a marked push for high-quality biosimilars [6] but a 
real change will only be seen once the regulatory agencies 
take concrete steps towards improving efficiency and trans-
parency of the processes, standardization of RBP require-
ments, establishing abridged review pathways, following a 
step-wise approach and accepting advanced analytical com-
parability data in lieu of confirmatory clinical studies.
Regulators are conservative by inclination and incen-
tivization, and are not minded to lead progressive change, 
even though it may lead to improvements for patients. It is, 
therefore, up to industry, which invented the products and 
their associated scientific underpinnings in the first place, 
to educate regulators on efficient review pathways. It is evi-
dent from this paper that many of the regulators essentially 
consider biosimilars to require only a slight variation of the 
traditional innovator’s drug review pathway, which is to deny 
completely the science and logic of biosimilarity and the 
benefits that it can confer. Requirements for approval of bio-
similars based upon a good scientific understanding will find 
no place for studies in animals, no place for local clinical 
studies, few reasons to ‘bridge’ a local version of the refer-
ence to a version approved in another jurisdiction and no 
reason to require clinical equivalence studies routinely, but 
it is for industry to bring these understandings to patients, 
payers, regulators and physicians alike.
4.1  Hypothesis to be Tested in Future Studies
• Removal of mandatory compliance with confirma-
tory clinical safety and efficacy studies would improve 
patients’ access to biosimilars.
• Adoption of verification and abridged regulatory review 
models would reduce the approval timelines.
• Establishment of harmonized biosimilar regulatory 
guidelines for the BRICS-TM countries will enhance 
development and approval timelines.
• Flexibilities in sourcing of RBP will result in develop-
ment of a common biosimilar development programme.
5  Conclusions
This study delves into the understanding and perception of 
the respondents regarding the efficiency and effectiveness 
of current regulatory processes for biosimilar products and 
gathers suggestions on potential improvements in this area. 
The study was based on the experience and expertise of 
those involved in the research and development of bio-
similars and provides a unique insight into the successes 
and challenges faced by the biosimilar industry at large. 
The findings suggested that the BRICS-TM industry faces 
significant challenges related to cost of development, effi-
ciency and transparency of processes, standardization of 
RBP requirements, availability of clear scientific advice 
and acceptance of advanced analytical comparability data 
in lieu of confirmatory clinical studies.
Despite availability of the Similar Biotherapeutic Prod-
ucts (SBP) guidelines issued by WHO [32–34], findings 
of this study indicate that the guidelines have been only 
partially implemented by the National Regulatory Agen-
cies (NRAs) of BRICS-TM countries, leaving their review 
practices open to interpretation. Hence, continued efforts 
towards a globally consistent approach to biosimilar devel-
opment and approval processes considering the regional 
differences in regulations appears to be essential. This 
can be ensured by following the concepts of a ‘step-wise 
approach’ and ‘head-to-head’ biosimilarity, which are the 
core of the regulatory guidelines of mature agencies such 
as the European Medicines Agency (EMA), the US FDA 
and WHO [35]. Such global adoption of regulatory guide-
lines modelled over existing templates could further expe-
dite approval and facilitate patients’ access to these medi-
cines. To achieve this, and to gain the trust and acceptance 
of biosimilars globally, education plays a crucial role [35]. 
Moreover, the role of the biopharmaceutical industry is 
very significant in balancing the need to account for regu-
latory variations against the costs of the studies required 
to seek biosimilar approvals in all geographic regions 
[36]. An in-depth knowledge of each region, early strate-
gic planning, and effective communication with regulatory 
agencies would be advantageous in achieving this [37]. 
Further, the understanding by new inexperienced manufac-
turers developing biosimilar products requires great care 
and attention regarding the development and production of 
these biological products and adhering to Good Manufac-
turing Practice (GMP) is essential. Also, the role of NRAs 
in overseeing these developments through GMP inspec-
tions is critical [38]. Thus, there is an immediate need to 
create a culture of quality within the organization to meet 
the challenges posed by complex biosimilar molecules 
[39]. This would enable manufacturers to provide con-
sistent production and quality control, thereby preventing 
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drift from the required specifications over time and would 
greatly influence the acceptance of biosimilars and their 
integration into daily practice [40].
The findings of this study have led to a number of rec-
ommendations that it is hoped will be considered by the 
BRICS-TM regulatory agencies:
1. The regulatory agencies in the BRICS-TM countries 
should consider timely provision of appropriate tai-
lor-made and binding scientific advice to companies 
engaged in biosimilar development. This should also be 
extended to clinical studies, if applicable.
2. The regulatory agencies should consider adopting shared 
evaluation, reliance and abridged regulatory review 
models for biosimilars.
3. The regulatory agencies should consider moving towards a 
step-wise approach to development and mandate non-clin-
ical data only in cases where it is fundamentally required.
4. The regulatory agencies should consider accepting 
advanced analytical comparability data in lieu of con-
firmatory clinical studies.
5. Regulatory agencies should consider accepting RBP 
sourcing from BRICS-TM countries other than their 
own, with a waiver of bridging studies to ease avail-
ability of multiple RBP lots and in order to facilitate 
common development programmes.
6. Regulatory agencies should consider standardizing the 
number of RBP lots for development and establish an 
agency for the timely supply of RBP with varied drug 
substance lots.
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